INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $118,000 | +257.6% | 6,372 | +114.9% | 0.00% | – |
Q2 2023 | $33,000 | -70.5% | 2,965 | -64.6% | 0.00% | – |
Q1 2023 | $112,000 | -30.4% | 8,378 | -35.7% | 0.00% | – |
Q4 2022 | $161,000 | +9.5% | 13,027 | +23.6% | 0.00% | – |
Q3 2022 | $147,000 | +2.1% | 10,537 | +1.6% | 0.00% | – |
Q2 2022 | $144,000 | -24.6% | 10,373 | -11.9% | 0.00% | – |
Q1 2022 | $191,000 | -32.0% | 11,768 | -32.0% | 0.00% | – |
Q4 2021 | $281,000 | +36.4% | 17,313 | +24.7% | 0.00% | – |
Q3 2021 | $206,000 | -87.1% | 13,884 | -82.7% | 0.00% | – |
Q2 2021 | $1,602,000 | -10.0% | 80,192 | +4.0% | 0.00% | -100.0% |
Q1 2021 | $1,780,000 | -5.5% | 77,102 | +1.2% | 0.00% | 0.0% |
Q4 2020 | $1,883,000 | -42.2% | 76,212 | -3.0% | 0.00% | 0.0% |
Q3 2020 | $3,256,000 | -38.0% | 78,538 | -28.3% | 0.00% | -50.0% |
Q2 2020 | $5,250,000 | -30.4% | 109,567 | -8.5% | 0.00% | -50.0% |
Q1 2020 | $7,542,000 | -53.7% | 119,788 | -8.8% | 0.00% | -33.3% |
Q4 2019 | $16,274,000 | +80.7% | 131,322 | -3.2% | 0.01% | +50.0% |
Q3 2019 | $9,005,000 | -9.1% | 135,726 | +9.1% | 0.00% | 0.0% |
Q2 2019 | $9,902,000 | -24.8% | 124,431 | +5.8% | 0.00% | -33.3% |
Q1 2019 | $13,161,000 | +39.0% | 117,653 | +25.3% | 0.01% | +20.0% |
Q4 2018 | $9,466,000 | -17.3% | 93,922 | +3.6% | 0.01% | 0.0% |
Q3 2018 | $11,450,000 | +18.5% | 90,615 | -21.3% | 0.01% | +25.0% |
Q2 2018 | $9,660,000 | +69.8% | 115,111 | +24.5% | 0.00% | +33.3% |
Q1 2018 | $5,689,000 | +2.6% | 92,467 | -2.6% | 0.00% | +50.0% |
Q4 2017 | $5,546,000 | +5.6% | 94,926 | +4.9% | 0.00% | -33.3% |
Q3 2017 | $5,253,000 | -48.1% | 90,510 | +8.3% | 0.00% | -40.0% |
Q2 2017 | $10,121,000 | +6.7% | 83,599 | -0.3% | 0.01% | 0.0% |
Q1 2017 | $9,483,000 | +3.9% | 83,847 | -0.2% | 0.01% | 0.0% |
Q4 2016 | $9,125,000 | -25.2% | 83,982 | +13.3% | 0.01% | -28.6% |
Q3 2016 | $12,197,000 | +1281.3% | 74,098 | +1097.6% | 0.01% | +600.0% |
Q2 2016 | $883,000 | +0.9% | 6,187 | -9.3% | 0.00% | 0.0% |
Q1 2016 | $875,000 | -89.4% | 6,823 | -87.6% | 0.00% | -80.0% |
Q4 2015 | $8,247,000 | +292.2% | 55,229 | +335.7% | 0.01% | +150.0% |
Q3 2015 | $2,103,000 | -42.8% | 12,676 | -16.8% | 0.00% | -33.3% |
Q2 2015 | $3,679,000 | -17.2% | 15,243 | -3.3% | 0.00% | 0.0% |
Q1 2015 | $4,444,000 | +129.8% | 15,761 | +27.2% | 0.00% | +200.0% |
Q4 2014 | $1,934,000 | -24.5% | 12,394 | +14.6% | 0.00% | -50.0% |
Q3 2014 | $2,560,000 | +61.0% | 10,817 | +61.1% | 0.00% | +100.0% |
Q2 2014 | $1,590,000 | +778.5% | 6,716 | +1121.1% | 0.00% | – |
Q1 2014 | $181,000 | +2916.7% | 550 | +587.5% | 0.00% | – |
Q3 2013 | $6,000 | – | 80 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Samsara BioCapital, LLC | 234,375 | $23,623,000 | 22.67% |
Boxer Capital, LLC | 600,000 | $60,474,000 | 7.47% |
DLD Asset Management, LP | 834,600 | $84,136,000 | 5.77% |
GREAT POINT PARTNERS LLC | 200,000 | $20,158,000 | 2.55% |
BB BIOTECH AG | 575,719 | $58,027,000 | 1.86% |
Elk Creek Partners, LLC | 207,657 | $20,930,000 | 1.74% |
ALTRINSIC GLOBAL ADVISORS LLC | 277,944 | $28,014,000 | 1.34% |
Sarissa Capital Management LP | 54,000 | $5,442,000 | 1.21% |
QCM Cayman, Ltd. | 2,181 | $220,000 | 0.90% |
Opus Point Partners Management, LLC | 3,534 | $356,000 | 0.78% |